trending Market Intelligence /marketintelligence/en/news-insights/trending/ns_c-nswqbnyuerpxehwvq2 content esgSubNav
In This List

Deciphera Pharmaceuticals closes $172M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Deciphera Pharmaceuticals closes $172M common stock offering

Deciphera Pharmaceuticals Inc. closed an underwritten public offering for gross proceeds of $172 million.

The company offered 4,300,000 common shares at $40 apiece.

J.P. Morgan and Piper Jaffray & Co. acted as joint book-running managers for the offering, with Canaccord Genuity LLC and JMP Securities LLC as lead managers. Nomura Securities International Inc. and Raymond James & Associates Inc. acted as co-managers.

Waltham, Mass.-based Deciphera Pharmaceuticals makes treatments for cancer.